Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2010 Feb 12;25(1):36–44. doi: 10.1007/s12250-010-3096-2

Immunogenicity of the spike glycoprotein of Bat SARS-like coronavirus

Yu-xuan Hou 1, Cheng Peng 1, Zheng-gang Han 1, Peng Zhou 1, Ji-guo Chen 2, Zheng-li Shi 1,✉
PMCID: PMC7090579  PMID: 20960282

Abstract

A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection.

Key words: SARS coronavirus (SARS-CoV), SARS-like coronavirus (SL-CoV), Spike glycoprotein, Humoral immune response, Cellular immune response

Footnotes

Foundation items: This work was supported by the State Key Program for Basic Research Grant (2005CB523004) from the Chinese Ministry of Science and Technology, the Knowledge Innovation Program Key Project administered by the Chinese Academy of Sciences (KSCX1-YW-R-07).

References

  • 1.Bai B., Hu Q., Hu H., et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS ONE. 2008;3:e2685. doi: 10.1371/journal.pone.0002685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Baric R. S., Fu K., Schaad M. C., et al. Establishing a genetic recombination map for murine coronavirus strain A59 complementation groups. Virology. 1990;177:646–656. doi: 10.1016/0042-6822(90)90530-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Berry J. D., Jones S., Drebot M. A., et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods. 2004;120:87–96. doi: 10.1016/j.jviromet.2004.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bisht H., Roberts A., Vogel L., et al. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334:160–165. doi: 10.1016/j.virol.2005.01.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chen Z., Zhang L., Qin C., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79:2678–2688. doi: 10.1128/JVI.79.5.2678-2688.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chou C. F., Shen S., Tan Y. J., et al. A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J Virol Methods. 2005;123:41–48. doi: 10.1016/j.jviromet.2004.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fouchier R. A., Kuiken T., Schutten M., et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature. 2003;423:240. doi: 10.1038/423240a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fu K., Baric R. S. Evidence for variable rates of recombination in the MHV genome. Virology. 1992;189:88–102. doi: 10.1016/0042-6822(92)90684-H. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Guan Y., Zheng B. J., He Y. Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278. doi: 10.1126/science.1087139. [DOI] [PubMed] [Google Scholar]
  • 10.He Y., Li J., Du L., et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006;24:5498–5508. doi: 10.1016/j.vaccine.2006.04.054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.He Y., Li J., Heck S., et al. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006;80:5757–5767. doi: 10.1128/JVI.00083-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.He Y., Li J., Jiang S. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem Biophys Res Commun. 2006;344:106–113. doi: 10.1016/j.bbrc.2006.03.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.He Y., Lu H., Siddiqui P., et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174:4908–4915. doi: 10.4049/jimmunol.174.8.4908. [DOI] [PubMed] [Google Scholar]
  • 14.He Y., Zhou Y., Liu S., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324:773–781. doi: 10.1016/j.bbrc.2004.09.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.He Y., Zhou Y., Wu H., et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004;173:4050–4057. doi: 10.4049/jimmunol.173.6.4050. [DOI] [PubMed] [Google Scholar]
  • 16.Ho T. Y., Wu S. L., Cheng S. E., et al. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun. 2004;313:938–947. doi: 10.1016/j.bbrc.2003.11.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ksiazek T. G., Erdman D., Goldsmith C. S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966. doi: 10.1056/NEJMoa030781. [DOI] [PubMed] [Google Scholar]
  • 18.Lau S. K., Woo P. C., Li K. S., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102:14040–14045. doi: 10.1073/pnas.0506735102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Li W., Moore M. J., Vasilieva N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Li W., Shi Z., Yu M., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676–679. doi: 10.1126/science.1118391. [DOI] [PubMed] [Google Scholar]
  • 21.Liu R. Y., Wu L. Z., Huang B. J., et al. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 2005;112:24–31. doi: 10.1016/j.virusres.2005.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Marra M. A., Jones S. J., Astell C. R., et al. The Genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404. doi: 10.1126/science.1085953. [DOI] [PubMed] [Google Scholar]
  • 23.Peiris J. S., Yuen K. Y., Osterhaus A. D., et al. The severe acute respiratory syndrome. N Engl J Med. 2003;349:2431–2441. doi: 10.1056/NEJMra032498. [DOI] [PubMed] [Google Scholar]
  • 24.Pfeffer L. M., Dinarello C. A., Herberman R. B., et al. Biological properties of recombinant alphainterferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489–2499. [PubMed] [Google Scholar]
  • 25.Poon L. L., Chu D. K., Chan K. H., et al. Identification of a novel coronavirus in bats. J Virol. 2005;79:2001–2009. doi: 10.1128/JVI.79.4.2001-2009.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ren W., Qu X., Li W., et al. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J Virol. 2008;82:1899–1907. doi: 10.1128/JVI.01085-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rota P. A., Oberste M. S., Monroe S. S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. doi: 10.1126/science.1085952. [DOI] [PubMed] [Google Scholar]
  • 28.Simmons G., Reeves J. D., Rennekamp A. J., et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoproteinmediated viral entry. Proc Natl Acad Sci USA. 2004;101:4240–4245. doi: 10.1073/pnas.0306446101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Stroher U., DiCaro A., Li Y., et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis. 2004;189:1164–1167. doi: 10.1086/382597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tang X. C., Zhang J. X., Zhang S. Y., et al. Prevalence and genetic diversity of coronaviruses in bats from China. J Virol. 2006;80(15):7481–7490. doi: 10.1128/JVI.00697-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Wang W., Ye L., Ye L., et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 2007;128:1–8. doi: 10.1016/j.virusres.2007.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Wang Y. D., Sin W. Y., Xu G. B., et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol. 2004;78:5612–5618. doi: 10.1128/JVI.78.11.5612-5618.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Woo P. C., Lau S. K., Li K. S., et al. Molecular diversity of coronaviruses in bats. Virology. 2006;351:180–187. doi: 10.1016/j.virol.2006.02.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yang Z. Y., Kong W. P., Huang Y., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428:561–564. doi: 10.1038/nature02463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yi C. E., Ba L., Zhang L., et al. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol. 2005;79:11638–11646. doi: 10.1128/JVI.79.18.11638-11646.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Zhong N. S., Zheng B. J., Li Y. M., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February. Lancet. 2003;362:1353–1358. doi: 10.1016/S0140-6736(03)14630-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhou Z., Post P., Chubet R., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006;24:3624–3631. doi: 10.1016/j.vaccine.2006.01.059. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES